We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,' the drug maker said.

The USFDA conducted an inspection at the company's Baska facility from 8 September 2025 to 19 September 2025 and has subsequently classified the inspection outcome as Official Action Indicated (OAI) ...

Shares of Sun Pharmaceutical Industries closed 2.77% lower on Thursday (December 18, 2025) at ₹1,745.35 apiece on the BSE after the U.S. Food and Drug Administration (U.S. FDA) classified the ...

Sun Pharmaceutical Industries declined 2.68% to Rs 1746.95 after the company announced that the US FDA, post an audit, has determined the Baska facility inspection classification as Official Action ...

Sun Pharma on Thursday said the US health regulator has classified its Baska facility in Gujarat under Official Action Indicated (OAI) category following an inspection. The US Food and Drug ...

Sun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action Indicated (OAI) by the US FDA following a recent inspection. Despite this ...

Weak US momentum and regulatory headwinds drag Sun Pharma below Sensex and Nifty despite steady domestic gains ...

The company is recalling the affected lot due to 'Failed Impurity/Degradation specifications,' the USFDA stated.

Sun Pharma Share Price: Shares of Sun Pharma fell over 3 per cent today after the firm said the US Food and Drug Administration classified the company's Baska facility as an Official Action Indicated, ...